Defects in apoptosis underpin both tumorigenesis and drug resistance, and because of
these defects chemotherapy often fails. Understanding the molecular events that contribute
to drug-induced apoptosis, and how tumors evade apoptotic death, provides a paradigm to
explain the relationship between cancer genetics and treatment sensitivity and should
enable a more rational approach to anticancer drug design and therapy.